Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab in AS or nr-axSpA
NCT02980705Phase 2Terminated
- Sponsor
- Sun Pharma
- Start
- Nov 2017
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of tildrakizumab in ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by Sun Pharma. Started Nov 2017; status: terminated.
02
Drugs
tildrakizumab
03
Conditions
ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT02980705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980705.